Business

Huawei Unveils HUAWEI WATCH D3 at ISH-ECS 2026

· GlobeWire Daily Business Desk · Source: www.prnewswire.com

2 min read

Key takeawaysThe 31st Scientific Meeting of the International Society of Hypertension and the 17th Annual Conference of the Emirates Cardiac Society (ISH-ECS 2026) concluded in Dubai, serving as a platform for global experts to discuss cardiovascular health. During the event, Huawei introduced the HUAWEI WATCH D3, a wearable device designed for medical-grade blood…
El HUAWEI WATCH D3 debuta en ISH-ECS 2026

Image: Huawei · Photo source · Resized and letterboxed to 16:9; no AI generation

Advancing Hypertension Management

The 31st Scientific Meeting of the International Society of Hypertension and the 17th Annual Conference of the Emirates Cardiac Society (ISH-ECS 2026) concluded in Dubai, serving as a platform for global experts to discuss cardiovascular health. During the event, Huawei introduced the HUAWEI WATCH D3, a wearable device designed for medical-grade blood pressure monitoring.

Key Innovations and Clinical Recognition

  • Medical-Grade Accuracy: The HUAWEI WATCH D3 utilizes oscilometric technology with an ultrathin airbag to provide precise readings. It is the first device of its kind to receive EU CE certification under the Medical Device Regulation (MDR) and Class II medical device registration in China.
  • Integration of Technology: The watch features a new mode for tracking blood pressure before and after physical activity, aimed at identifying anomalies and supporting informed exercise routines.
  • Clinical Validation: International guidelines from organizations such as the European Society of Hypertension and ISH are increasingly recognizing wrist-worn, inflatable-cuff devices for clinical blood pressure self-monitoring.

Collaborative Research Initiatives

To further validate and expand the use of wearable technology, Huawei has launched the 'Wearable Blood Pressure Measurement Innovation Fund' in partnership with ISH. Early research projects involve institutions from Sri Lanka, the UK, and China.

Furthermore, Huawei is conducting studies with the Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, to test a hybrid, minimally intrusive Ambulatory Blood Pressure Monitoring (ABPM) approach. This method aims to reduce the frequency of cuff inflations while maintaining measurement accuracy for 24-hour profiles.

*Note: Verification of product specifications and clinical claims should be cross-referenced with official Huawei press releases and relevant peer-reviewed medical journals or health authority certifications.*

Share this article
Read the original source: El HUAWEI WATCH D3 debuta en ISH-ECS 2026

AI-assisted reporting; source claims are attributed and have not been independently verified.

About the author

GlobeWire Daily Business Desk — AI-assisted news based on attributed published sources.

More to read